Fatigue and muscle soreness.
Conditions
Interventions
Intervention 1: Intervention group: The participants (37 people) will receive curcumin oral supplement in the form of tablets with a dose of 500 mg with the trade name (Curcuma ® ). The time to take t
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Women with normal menopause At least one year after amenorrhea Sufficient literacy to complete the questionnaire or accompany a literate person in the family Age minimum 40 years and maximum 60 years
Exclusion criteria
Exclusion criteria: Abuse of tobacco and alcohol Use of herbal medicines Occurrence of a stressful event (such as divorce, death of first-degree family members, diagnosis of incurable disease for a family member within the last three months, and loss of job) Psychiatric or systemic disorders (such as cardiovascular, digestive, hepatic, blood, endocrine, and gallstones) Taking any medication that affects hot flashes (clonidine, methyldopa, gabapentin, SSRIs, SNRIs, soy isoflavones), thyroid disease (as reported by women) Taking antidepressants (such as serotonin and noradrenaline reuptake inhibitors, antihistamines, barbiturates, narcotics, diazepam, amphetamines, and cocaine) History of allergy to turmeric or other drugs, allergy to certain foods and food dyes Taking anticoagulants such as heparin, aspirin, clopidogrel, dipyridamole, warfarin, enoxaparin and ticlopidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue. Timepoint: At the beginning of the study and 8 weeks after the start of consumption. Method of measurement: Short questionnaire of the perimenopausal fatigue scale.;Muscle soreness. Timepoint: At the beginning of the study and 8 weeks after the start of consumption. Method of measurement: MUSCULOSKELETAL HEALTH QUESTIONNAIRE (MSK-HQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: At the beginning of the study and 8 weeks after the start of consumption. Method of measurement: Beck Depression Inventory (BDI-13). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Mashayekh Amiri
Tabriz University of Medical Sciences
Outcome results
None listed